Core Viewpoint - WuXi Biologics (02269) announced the issuance of 7.5 million ordinary shares on November 12, 2025, as part of the exercise of options under its pre-IPO share option plan adopted on January 5, 2016, and revised on August 10, 2016 [1] Summary by Relevant Sections - Share Issuance Details - The company will issue 7.5 million ordinary shares [1] - This issuance is related to the exercise of options under a previously established share option plan [1] - Historical Context - The share option plan was initially adopted on January 5, 2016, and revised on August 10, 2016 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司*（於開曼群島註冊成立的有限公司）*僅供識別 呈交日期： 2025年11月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發 ...

Group 1 - The National Medical Products Administration of China has approved 2 innovative drugs and 2 innovative medical devices for market entry since November, indicating a shift from being a "technology follower" to a "technology leader" with 4,804 innovative drugs in the pipeline, ranking second globally [1] - In 2025, negotiations for the national basic medical insurance drug catalog and commercial insurance innovative drug catalog pricing have been completed, with 120 companies participating, including 127 drugs for basic medical insurance and 24 for commercial insurance [1] Group 2 - The Hong Kong innovative drug ETF (SH520700) has shown a 2.13% increase, reflecting a clear trend of innovation going global, with ongoing benefits from drug review reforms and supportive policies [2] - The Chinese innovative drug industry has entered its 2.0 era, transitioning from "importing and imitating" to "innovative output," with various forms of internationalization such as license out and new co [2] - The ETF tracks the CSI Hong Kong Stock Connect Innovative Drug Index, which includes leading companies like BeiGene, Innovent Biologics, and WuXi AppTec, focusing on innovative drug development, production, and services in the Hong Kong market [2]

Group 1 - The innovative drug sector is experiencing an upswing, with companies like BeiGene rising over 7% and 3SBio increasing over 4%, contributing to a 2.59% rise in the Hang Seng Innovative Drug ETF (159316) [1] - BeiGene announced a total revenue of $1.4 billion for Q3 2025, representing a 41% year-on-year growth, while the global revenue for its drug, Brukinsa, reached $1 billion, marking a 51% increase [1] - Pfizer's acquisition of Metsera for nearly $10 billion is seen as a positive development for China's innovative drug industry, indicating a growing openness from multinational pharmaceutical companies towards innovative drugs [1] Group 2 - In the first half of 2025, the total value of "going abroad" transactions for Chinese innovative drugs reached $48 billion, surpassing the total for the entire year of 2024, with the $11.4 billion deal between Innovent Biologics and Takeda setting a new high for this year [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, focusing on core enterprises in the innovative drug industry, excluding CXO companies [2] - The ETF provides a convenient tool for investors to access leading innovative drug companies in the Hong Kong stock market, with major holdings including BeiGene, Innovent Biologics, WuXi Biologics, and CanSino Biologics [2]

Group 1: Market Overview - The Hang Seng Index experienced a two-day increase, rising over 400 points, with a closing gain of 47 points or 0.18%, ending at 26,696 points [3] - The market showed volatility, reaching a high of 26,788 before facing selling pressure, dropping to a low of 26,511 [3] - The total market turnover for the day was 210.23 billion HKD [3] Group 2: Company News - Far East Development (00035) is in discussions to sell certain rights of the Ritz-Carlton hotel in Perth to Shangri-La Group for an initial payment of 20 million AUD (approximately 101 million HKD) [10] - GAC Group (02238) has signed a comprehensive strategic cooperation agreement with CATL (03750) to enhance collaboration in smart chassis and battery swapping technologies over the next ten years [11] - JD.com (09618) reported that its daily order volume for its food delivery service exceeded 25 million, with over 200,000 merchants and more than 150,000 full-time delivery riders [12] Group 3: Industry Insights - UBS's China equity investment director noted that the valuation re-evaluation phase for Chinese stocks may have ended, with a focus shifting to fundamental factors [6][7] - JPMorgan Private Bank predicts that gold prices could exceed 5,000 USD per ounce by the end of next year, driven by purchases from central banks in emerging markets [8]

Core Viewpoint - The Hong Kong medical sector is experiencing a strong performance, with the CSI Hong Kong Stock Connect Medical Theme Index rising by 2.19%, driven by leading stocks such as BeiGene and Ping An Good Doctor [1][2]. Group 1: Market Performance - The Hong Kong medical ETF (159366) has increased by over 2%, and over the past three months, it has accumulated a rise of 1.74% as of November 11, 2025 [1][2]. - The CSI Hong Kong Stock Connect Medical Theme Index includes 50 listed companies in the medical device, medical services, and pharmaceutical sectors, reflecting the overall performance of the medical sector within the Stock Connect [2]. Group 2: Company Performance - BeiGene reported a total revenue of $1.4 billion for Q3, marking a 41% year-on-year increase, with a GAAP net profit of $125 million, reversing a loss from the previous year [4]. - The innovative drug sector is showing strong growth, with a 23.34% increase in revenue year-on-year, and CXO companies seeing a 55.90% increase in net profit [4]. Group 3: Market Trends - The CRO service market in China is projected to grow from 52.2 billion yuan in 2020 to 87.8 billion yuan by 2024, with a compound annual growth rate (CAGR) of 13.9% [3]. - The overall performance of the pharmaceutical and biotechnology sector has been under pressure, with a decline in revenue and net profit by 1.9% and 4.8% respectively for the first three quarters of 2025 [4].

Market Overview - The Hong Kong stock market showed little change, with the Hang Seng Index and the Hang Seng China Enterprises Index closing at 26,696 points and 9,461 points, respectively, both up by 0.2% [1] - Total trading volume was HKD 210.2 billion, slightly lower than the previous day's HKD 214.8 billion, indicating a mixed market sentiment [1] - Real estate, construction, finance, and telecommunications sectors saw increases of 1.4%, 0.8%, and 0.6%, while non-essential consumer goods, energy, and healthcare sectors declined by 0.4%, 0.3%, and 0.1% [1] Company Highlights - XPeng Motors (9868 HK) surged by 17.9%, reaching a one-year high, following the launch of its new generation IRON robot, expanding its business from electric vehicles to robotaxis and humanoid robots [4] - WuXi AppTec (2269 HK) and Semiconductor Manufacturing International Corporation (981 HK) both experienced declines of 2.7% [1] - Weichai Power (3393 HK) saw a significant increase of 6.9%, with trading volume doubling, attributed to the rising demand in the AI industry and data center electricity consumption [5] Industry Dynamics - In the automotive sector, China's October vehicle sales increased by 8.8% year-on-year to 3.32 million units, a decrease from September's 14.9% growth [3] - The healthcare sector's Hang Seng index fell by 0.2%, with major companies showing little volatility; however, BeiGene (6160 HK) rose by 1.0% after reporting strong Q3 results [4] - The renewable energy sector experienced fluctuations, with notable declines in the photovoltaic segment, including Xinyi Solar (968 HK) down by 2.0% and Xinyi Energy (3868 HK) down by 1.5% [5]

Group 1 - The Hong Kong stock market opened slightly higher, with the Hang Seng Index at 26,754.93 points, up 58.52 points, a gain of 0.22% [1] - The Hang Seng Tech Index reported 5,939.69 points, increasing by 15.30 points, a rise of 0.26% [3] Group 2 - Heisai-W (HK02525) announced a net revenue of RMB 795 million for Q3, a year-on-year increase of 47.5%, and a net profit of RMB 256 million, turning from loss to profit. The full-year net profit guidance was raised to between RMB 350 million and RMB 450 million, with Q4 net revenue expected to be between RMB 1 billion and RMB 1.2 billion, a year-on-year growth of approximately 39% to 67%. However, Heisai's stock fell over 10% in early trading [4] - China General Nuclear Power New Energy (HK01811) reported a cumulative power generation of 15,753.4 GWh for the first 10 months, a decrease of 3.5% year-on-year [6] - Dongyao Pharmaceutical-B (HK01875) announced a revenue of RMB 622 million for the nine months ending September 30, 2025, with a net loss attributable to equity holders of RMB 3.371 million [6] Group 3 - The innovative drug sector saw collective gains in early trading, with BeiGene rising over 4%, Kailaiying up over 1.8%, and Zhaoyan New Drug, WuXi AppTec, and WuXi Biologics each increasing by over 1% [8] - In other sectors, tech stocks showed mixed performance, with Xiaomi up over 2%, Tencent and NetEase rising over 1%, while Alibaba and Baidu fell over 2%. Real estate stocks were active, with Shimao Group increasing over 3%, and some automotive stocks opened higher, with XPeng Motors up over 2% [9] Group 4 - According to China Merchants Securities, the recent volatility in the Hong Kong stock market is partly due to investors taking profits, but this expectation gap creates investment opportunities. With a turning point in the U.S. government shutdown and an upward revision of external liquidity expectations, the market may open new upward space after consolidation [10]

Group 1 - The Hong Kong stock market opened slightly higher today, with the Hang Seng Index at 26,754.93 points, up 58.52 points, or 0.22% [1] - The Hang Seng Technology Index rose to 5,939.69 points, increasing by 15.30 points, or 0.26% [3] Group 2 - HeSai-W (HK02525) reported a net income of RMB 795 million for Q3, a year-on-year increase of 47.5%, and a net profit of RMB 256 million, turning from loss to profit. The full-year net profit guidance has been raised to between RMB 350 million and RMB 450 million, with Q4 revenue expected to be between RMB 1 billion and RMB 1.2 billion, a year-on-year growth of approximately 39% to 67% [2] - China General Nuclear Power New Energy (HK01811) announced a cumulative power generation of 15,753.4 GWh for the first ten months, a year-on-year decrease of 3.5% [6] - Dongyao Pharmaceutical-B (HK01875) reported a revenue of RMB 622 million for the nine months ending September 30, 2025, with a net loss attributable to equity holders of RMB 3.371 million [6] Group 3 - The innovative drug sector saw a collective rise in early trading, with companies like BeiGene up over 4%, Kailaiying up over 1.8%, and others like Zhaoyan New Drug, WuXi AppTec, and WuXi Biologics rising over 1% [6] - In the tech sector, Xiaomi rose over 2%, while Tencent and NetEase increased by over 1%. However, Alibaba and Baidu fell by over 2% [8]

Group 1 - The Hong Kong innovative drug sector experienced a strong performance, with companies like 3SBio and BeiGene rising by 6%, and others like InnoCare and CanSino Biologics increasing by 4.36% and 3.72% respectively, contributing to a 2% rise in the Hang Seng Pharmaceutical ETF [1] - BeiGene reported a total revenue of $1.4 billion for Q3, marking a 41% year-on-year increase and achieving a historical high for the same period, with a GAAP net profit of $125 million, reversing previous losses [1] - The negotiation for the 2025 National Basic Medical Insurance Drug List and the pricing discussions for innovative drugs in commercial insurance were completed last week, with expectations of active business development transactions in November and December, coinciding with major industry conferences [1] Group 2 - The Hong Kong Central Enterprise Dividend ETF saw a rise of over 1%, accumulating an 11% increase since September 26, indicating renewed investor interest in high-dividend assets as year-end approaches [1] - The Central Enterprise Dividend ETF includes major stocks such as COSCO Shipping Holdings, Orient Overseas International, CITIC Bank, China Construction Bank, China National Offshore Oil Corporation, and PetroChina [2] - The Hang Seng Pharmaceutical ETF, representing the global pharmaceutical industry chain, increased by 2.85%, with top-weighted stocks including BeiGene, WuXi Biologics, InnoCare, China National Pharmaceutical Group, and 3SBio [2]